The team
Lightning Health isn’t just a market access consultancy with another digital tool. We are a team of highly experienced market access professionals and leading industry and policy stakeholders from around the world.

Our experience spans industry, government and strategic consultancy. We are digitally led, solution oriented and support optimal patient access and uptake across healthcare systems.

We take pride in building dynamic, collaborative partnerships that provide a true extension to your team.
Eleanor Butler

Eleanor has experience in Market Access and Health Management, including roles in Market Access Consulting and strategic change management projects for the NHS (Gynaecology, Kings College hospital London and Emergency Department and Trauma, Royal London Hospital). Her current research interest is on rare diseases and Advanced Therapy Medicinal Products (ATMPs) and the complex challenges they present to the current global HTA and payer infrastructure.
Eleanor is experienced in the development of pricing and market landscape assessments and launch strategy in the EU markets, including Central and Eastern Europe and US. Other projects include the development of global payer value messages, price optimization, development of a global master pricing database and literature review for PMA assessment.

Eleanor is well-practised in primary and secondary qualitative and quantitative research including systematic literature review and stakeholder interviews.

Most recently, she worked as a Senior Analyst at Remap Consulting, delivering global launch and price optimisation strategy for new medicines. Recent engagements include the assessment of commercial opportunity in EU5 and Central and Eastern European countries including payer research to inform global launch strategies. Eleanor has also authored an ISPOR poster on the impact of the modified NICE cancer drugs fund process on patient access to novel oncology drugs in England.

Eleanor obtained her MSc Health Management from City, University of London, and has led a systematic literature review with the Global Health WC2 Network, regarding interventions for social isolation and loneliness in older people


“Utilisation of primary research, engaging expert stakeholders, to explore the current treatment landscape from all perspectives (payer, physician, patient, payer, political) is key to ensuring innovative medicines reach those who need them in a timely manner”

Stuart Hurst
Executive Advisor (Launch Excellence)

Stuart has over thirty years’ experience in the pharmaceutical industry. During this time, he has worked across sales, marketing, public affairs and market access. Stuart started his pharmaceutical career as a Regional Manager with Servier before moving to Astra (before the merger with Zeneca) where his roles included NHS Facilitator (an early market access role) and regional controller.

Stuart had a number of roles at Pfizer, starting in Sales Management before setting up the Market Access team, one of the first in the UK at the time. Stuart then moved to Pfizer’s Government Affairs team in Brussels, before joining Eli Lilly as Head of European Public Affairs. There he was responsible for a cross-functional team covering Government Affairs, Communications, Policy Development, Patient Advocacy and Corporate Responsibility.

More recently, Stuart has focussed on rare diseases. Firstly with Synageva as VP, European Market Access & Government Affairs, where he took an ultra-orphan medicine from phase III results to being ready for pricing & reimbursement submission in all major markets in nine months. He then joined Akcea as Head of Global Market Access, Pricing and Reimbursement and established the function at global and country level, prior to the launch of an ultra-orphan in mid-2019.

Stuart is now working as an Independent Consultant supporting biotech companies looking to commercialise medicines for rare diseases internationally. His work includes commercial strategy & sequencing, global market access capacity and competency development, market access due diligence and talent acquisition.

Dr Gary Owens
Executive Advisor (US)

Dr Owens served as the Vice President of Medical Management and Policy at Independence Blue Cross (IBC) for 22 years with responsibilities for medical and pharmacy management, technology evaluation and medical policy.

Among his accomplishments at IBC was the development of their medical policy process with on-line access, and the launch of a coordinated care management approach to medical and pharmacy management. He was also in charge of the 2006 launch of FutureScripts, IBC’s wholly owned Pharmacy Benefit Manager (PBM). Forming his own consulting practice in 2007, Dr Owens provides strategic and tactical consulting services to a wide range of clients including pharmaceutical manufacturers, device manufacturers and other developers of new technology.

He has presented extensively on managed care, including at conferences of the Academy of Managed Care Pharmacy (AMCP), the National Association of Managed Care Physicians (NAMCP), and the Association for Value-Based Cancer Care. He has written 120 articles and editorials on managed care, pharmacy, and biotechnology, which have been published in American Health and Drug Benefits, The Journal of Managed Care Medicine, The American Journal of Managed Care, Journal of Managed Care and Speciality Pharmacy and Disease Management.

Dr Owens is the Past Chair of the Arthritis Foundation of Eastern PA and he was a former member of the Foundation’s Northeast Regional Board of Directors. Dr Owens was the first physician to serve (2014-2018) as a Board member of the Academy of Managed Care Pharmacy.